Nkarta, Inc. $NKTX Stock Holdings Lifted by Monaco Asset Management SAM

Monaco Asset Management SAM increased its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 24.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,970,910 shares of the company’s stock after buying an additional 387,538 shares during the period. Nkarta comprises approximately 0.2% of Monaco Asset Management SAM’s holdings, making the stock its 24th biggest position. Monaco Asset Management SAM owned 2.77% of Nkarta worth $4,080,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Nkarta by 0.8% in the second quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock worth $2,006,000 after acquiring an additional 10,065 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Nkarta by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company’s stock worth $1,253,000 after purchasing an additional 80,211 shares during the last quarter. AQR Capital Management LLC boosted its position in Nkarta by 300.5% during the 1st quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock valued at $1,237,000 after purchasing an additional 504,272 shares during the period. Peapod Lane Capital LLC grew its stake in Nkarta by 11.0% during the 2nd quarter. Peapod Lane Capital LLC now owns 663,850 shares of the company’s stock worth $1,102,000 after buying an additional 65,605 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in Nkarta by 4.0% in the second quarter. BNP Paribas Financial Markets now owns 231,081 shares of the company’s stock worth $384,000 after buying an additional 8,968 shares during the period. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Trading Down 1.3%

Shares of NASDAQ:NKTX opened at $2.33 on Friday. The company has a 50 day moving average of $2.04 and a 200-day moving average of $2.06. The firm has a market cap of $165.50 million, a P/E ratio of -1.69 and a beta of 0.54. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $2.74.

Insider Activity

In other news, CEO Paul J. Hastings sold 26,046 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $2.07, for a total value of $53,915.22. Following the sale, the chief executive officer owned 390,023 shares of the company’s stock, valued at approximately $807,347.61. The trade was a 6.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus reduced their price target on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 11th. Wall Street Zen raised shares of Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research report on Monday, December 29th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.25.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.